SI-BONE, Inc. (SIBN) Q2 2024 10-Q Summary
Business Context and Reporting Period
SI-BONE, Inc. is a medical device company focused on sacropelvic anatomy solutions, primarily through its iFuse implant systems. This report covers the quarterly period ended June 30, 2024. The company operates as a single reportable segment, deriving the majority of its revenue from the United States.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $39.97 million | $33.31 million | $77.84 million | $66.01 million |
| Gross Profit | $31.58 million | $26.99 million | $61.44 million | $53.77 million |
| Gross Margin | 79% | 81% | 79% | 81% |
| Net Loss | $(8.94) million | $(11.21) million | $(19.84) million | $(22.33) million |
| Diluted EPS | $(0.22) | $(0.30) | $(0.48) | $(0.61) |
| Cash & Investments | $151.53 million (as of June 30, 2024) | |||
| Long-Term Debt | $36.15 million (as of June 30, 2024) | |||
| Operating Cash Flow | N/A | $(13.91) million | $(14.34) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 20% year-over-year in Q2 2024, driven primarily by a $6.7 million increase in U.S. revenue due to higher case volumes and an expanded product portfolio.
- Margin Compression: Gross margin decreased from 81% to 79% due to changes in procedure and product mix.
- Expense Increases: Total operating expenses rose 7% to $41.65 million. Sales and marketing expenses increased by $1.48 million (5%), largely due to higher commissions and training costs. R&D expenses increased 19% due to product development activities and headcount growth.
- Interest Income: Interest income increased 27% to $2.02 million, reflecting higher interest rates on marketable securities.
- Accounting Change: The company extended the useful life of instrument trays from three to five years effective January 1, 2024, reducing depreciation expense by $0.5 million for the quarter.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash and marketable securities ($151.5 million) are sufficient to fund operations for at least the next 12 months. However, the company has an accumulated deficit of $420.3 million and expects to incur additional losses.
- Debt Covenants: The company is in compliance with debt covenants. However, access to the $15.0 million revolving credit line is currently restricted. To access future advances, the company must redirect customer payments and transfer cash balances back to First-Citizens Bank & Trust Company.
- Product Pipeline: The company launched iFuse INTRA in January 2024. Clinical trial results for the SILVIA study are anticipated in 2025.
- Risks: Key risks include reliance on third-party payors for reimbursement, supply chain disruptions, competition, and the need for additional capital to support inventory and instrument tray deployment for new products.
- Subsequent Event: On July 18, 2024, the company extended its corporate headquarters lease in Santa Clara, California, for an additional 14 months.
Investor Verification Checklist
- Verify the status of the revolving credit line restriction and the timeline for redirecting customer payments to First-Citizens Bank.
- Monitor the impact of the new iFuse INTRA product on revenue mix and gross margins in upcoming quarters.
- Review the company's cash burn rate relative to its $151.5 million liquidity position to assess the runway for future capital raises.
- Track the progress of the SILVIA clinical trial and potential reimbursement implications for the iFuse-TORQ product.
- Assess the sustainability of the 20% revenue growth rate given the seasonal nature of the business and competitive landscape.